CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant regimen for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Evaluate published data to guide the selection and duration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, considering recently presented clinical research and incorporating available and recently approved targeted agents and regimens.
  • Design an approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Erika Hamilton, MD
  Director, Breast and Gynecologic Research Program
  Sarah Cannon Research Institute/Tennessee Oncology
  Nashville, Tennessee
  
  Consulting Agreements (Paid to Institution): Arcus Biosciences,Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, Greenwich LifeSciences Inc, H3 Biomedicine, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Novartis, Orum Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Relay Therapeutics, Seagen Inc, Silverback Therapeutics; Contracted Research (Paid to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Institute, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Ellipses Pharma, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Incyte Corporation, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, ORIC Pharmaceuticals Inc, Orinove Inc, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Transcenta Holding Ltd, Treadwell Therapeutics, Verastem Inc, Vincerx Pharma, Zenith Epigenetics, Zymeworks Inc.
  
  Sara A Hurvitz, MD
  Professor of Medicine
  Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
  David Geffen School of Medicine at UCLA
  Medical Director, Clinical Research Unit
  Jonsson Comprehensive Cancer Center
  Santa Monica, California
  
  Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Greenwich LifeSciences Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc; One-Time Talk: Daiichi Sankyo Inc; Nonrelevant Financial Relationship: Ideal Implant (spouse).
  
  Ian E Krop, MD, PhD
  Associate Director, Clinical Research
  Director, Clinical Trials Office
  Chief Clinical Research Officer
  Yale Cancer Center
  New Haven, Connecticut
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group, MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.
  
  Shanu Modi, MD
  Member and Attending
  Breast Medicine Service
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, MacroGenics Inc, Seagen Inc; Contracted Research (To My Institution): AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Seagen Inc.
  
  Sara M Tolaney, MD, MPH
  Chief, Division of Breast Oncology
  Associate Director, Susan F Smith Center for Women's Cancers
  Senior Physician
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, ARC Therapeutics, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Mersana Therapeutics Inc, Myovant Sciences, Novartis, Odonate Therapeutics, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer Inc, Sanofi, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Puma Biotechnology Inc, and Seagen Inc.
  
  Release date: December 2022
  Expiration date: December 2023